Biotek-snakken — Juni 2023
-
Højt profileret læge og iværksætter med i Stenocares aktieudvidelse
https://www.proinvestor.com/boards/112991 -
Curasight A/S reports positive preclinical results with uTREAT[
] in aggressive brain cancer (glioblastoma)
7.6.2023 08.28 • MarketWire •Data from the study showed that uTREAT[
], when administered to a preclinical model of human aggressive brain cancer, effectively inhibited tumor growth. Animals receiving uTREAT[] survived longer compared to animals not treated with uTREAT[]. These data demonstrates the potential for uTREAT[] to be used as a radioligand the -
the treatment of aggressive brain cancer and supports further development for this treatment.
"We are extremely encouraged by these results, which further affirm our commitment to advancing our theranostic platform, comprising uTRACE[] and uTREAT[], for evaluation in patients with aggressive brain cancer. The urgent need to enhance therapeutic outcomes in this challenging disease drives our strategic pursuit," commented Ulrich Krasilnikoff, CEO of Curasight. -
An FDA advisory panel has voted 6-0 in
favour of recommending that Eisai and Biogen's Alzheimer's drug Leqembi be granted full approval. https://firstwordpharma.com/story/5750049 -
Stenocares emission overtegnet med 127% https://www.proinvestor.com/boards/113159
-
Data fra ICML ser flotte ud https://twitter.com/majorajay/status/1668909113743376386
-
-
Kort video - Bavarian Nordic ' Novo Nordisk ' Zealand Pharma ' Anavex ' Stenocare ' Brain+
Efter kvartalsregnskaberne er afsluttede, vælter det ikke ligefrem ud med store nyheder fra de forskellige selskaber generelt. Helge Larsen koncentrerer sig i denne opdatering om aktiekursudklingen i nogle af de mest omtalte selskaber på ProInvestor.com. https://www.proinvestor.com/boards/113234
-
Saniona går da godt deropad i disse uger.. købte i 2.9 for et par mdr siden.. i denne uge er den oppe i 11.. kan ikke finde noget nyt.. men som tidligere nævnt herinde, ligger der et enormt potentiale i deres platform og evne til at udvikle aktive stoffer.
-
BIOVICA: KEMPEN INLEDER MED KÖPREKOMMENDATION
16.6.2023 09.50 • Nyhetsbyrån Direkt •STOCKHOLM (Nyhetsbyrån Direkt) Kempen inleder bevakning av Biovica med rekommendation köp och riktkurs 30 kronor.
Det rapporterar internationell media.Biovica handlades kring 7 kronor vid 9.50-tiden, upp drygt 10 procent jämfört med torsdagens stängning.
-
Jazz........nej, der er ikke noget nyt i Saniona udover rygter om Tesofensine er ved at blive endelig godkendt i Mexico, samt det faktum, at Saniona er i tæt dialog og forhandlinger med 2 partnere, som vil sikre dem økonomisk mange år frem. Sker dette, så skal ATH i kurs 52 SEK testes igen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind